Researcher preparing a microplate for a metabolic receptor assay

Metabolic · Laboratory protocol

Tirzepatide

Dual agonist at GIPR and GLP-1R, 39 residues with a C20 fatty-diacid arm. No glucagon-receptor arm, which is the design difference from retatrutide.

For laboratory research use only. Material is supplied as a research reference standard and is not approved by Health Canada. Protocols below are compiled from published literature and supplier documentation; they are reference information, not medical advice. Anyone with a health condition or on medication should speak to a physician first.

Before you begin

• Lot-matched certificate and laboratory notebook
• Calibrated pipettes, low-binding tubes and suitable PPE
• Validated solvent, assay reagents and model-specific SOP
• Appropriate positive, negative and vehicle controls

Workflow

1Review the lot-matched COA and record identity, purity, batch number and received condition.
2Let the sealed vial equilibrate to room temperature before opening to limit condensation.
3Calculate the target stock concentration with C = mass / volume. Use only a solvent validated for the planned assay.
4Add solvent slowly down the vial wall, mix gently and avoid vortexing unless the validated method permits it.
5Prepare a log-spaced pilot concentration series; determine the usable range empirically instead of assuming a biological dose.
6Run the defined controls and technical replicates alongside every plate or experiment.
7Record preparation time, temperature, equipment, deviations and raw-data file locations.

Assay design

Usually paired head-to-head with a mono-agonist reference on the same plate, so the dual-receptor signature is measured against a known single-arm control rather than a historical curve.

Required controls

Vehicle-only negative control
Matched receptor-null cell line
Validated reference agonist
Untreated viability control

Reported protocol

Weeks 1-4: 2.5 mg once weekly
Weeks 5-8: 5.0 mg once weekly
Escalation steps: Increase by 2.5 mg every 4 weeks, up to 15 mg maximum
Route: Subcutaneous

Diluent

Sterile bacteriostatic water (0.9% benzyl alcohol) for multi-withdrawal stock, or sterile water for injection where a preservative-free stock is required by the assay.

Compound-specific: Bacteriostatic or sterile water only, for the same reason as the other lipidated incretin analogs. Discard any vial that does not go fully clear.

Reconstitution concentrations

Solvent volume sets the stock concentration for this 20 mg vial. Lower volume gives a more concentrated stock and smaller working aliquots; higher volume gives a more dilute stock that is easier to measure accurately.

Stock concentration by solvent volume for a 20 mg vial
Solvent added	Stock concentration	Per 0.1 mL	Per unit (U-100)
1 mL	20 mg/mL	2 mg	200 mcg
2 mL	10 mg/mL	1 mg	100 mcg
3 mL	6.67 mg/mL	666.67 mcg	66.67 mcg

Working range

Comparative agonism work runs a log-spaced series across the sub-nanomolar to nanomolar band. Because the GIPR and GLP-1R arms differ in potency, a single fixed concentration will misrepresent the molecule.

Usually paired head-to-head with a mono-agonist reference on the same plate, so the dual-receptor signature is measured against a known single-arm control rather than a historical curve.

Stability

Lyophilized: Stable as supplied, sealed and dry, at the certificate temperature.
In solution: Determine empirically for your solvent and container. Aliquot rather than repeatedly re-entering one vial.

Handling notes

Equilibrate to room temperature before opening.
Add solvent slowly down the wall; swirl, never vortex.
Use low-binding plasticware for dilute working solutions.
Run tirzepatide and any comparator on the same plate, same passage, same day.

Documentation checklist

Record lot and COA, mass balance, solvent and concentration, preparation timestamp, storage history, plate map, replicate plan, instrument settings, exclusions and deviations. Preserve raw data and analysis code with the experiment record.